Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by (90)Yibritumomab tiuxetan: Ten year follow-up of the phase 2 ECOG-ACRIN study E1499.
Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by (90)Yibritumomab tiuxetan: Ten year follow-up of the phase 2 ECOG-ACRIN study E1499. Leukemia Smith, M. R., Hong, F., Li, H., Gordon, L. I., Gascoyne, R. D., Paietta, E. M., Advani, R. H., Forero-Torres, A., Horning, S. J., Kahl, B. S. 2016View details for DOI 10.1038/leu.2016.305
View details for PubMedID 27780968